Hashimoto’s thyroiditis does cause thyroid nodules. The chronic inflammation that defines Hashimoto’s directly promotes nodule formation, and roughly 20% to 30% of people with the condition develop them. That rate increases with age, making nodules one of the more common complications of living with Hashimoto’s long term.
How Hashimoto’s Leads to Nodule Formation
In Hashimoto’s, your immune system attacks thyroid tissue, triggering ongoing inflammation. Over time, this persistent assault damages and reshapes the gland. Immune cells flood the thyroid, destroying healthy tissue and creating patches of scarring and irregular cell growth. These areas of disrupted tissue can cluster into distinct lumps, which are the nodules you’d see on an ultrasound.
There’s also a hormonal component. As the immune attack damages your thyroid’s ability to produce hormones, your pituitary gland responds by releasing more thyroid-stimulating hormone (TSH) to compensate. Elevated TSH acts like a growth signal to thyroid cells, encouraging them to multiply. That combination of inflammation-driven tissue damage and TSH-driven cell growth creates ideal conditions for nodules to form.
True Nodules vs. Pseudonodules
Not every lump that appears on a Hashimoto’s thyroid is a true nodule. The patchy inflammation characteristic of the disease can create areas of uneven tissue that look like nodules on a standard ultrasound but are actually just inflamed clusters of immune cells. These are called pseudonodules, and they don’t carry the same clinical significance as true nodules.
Telling the two apart can be tricky. On conventional grayscale ultrasound, the background of a Hashimoto’s thyroid is already coarse and uneven, making it harder to identify distinct nodules against the noise. A technique called sonoelastography, which measures tissue stiffness, has shown improved accuracy in distinguishing true nodules from pseudonodules. Fine needle aspiration biopsy remains the gold standard when there’s uncertainty, but better imaging can reduce the number of unnecessary biopsies.
Why Imaging Is Less Straightforward With Hashimoto’s
The standard scoring system radiologists use to evaluate thyroid nodules, called TI-RADS, assigns risk levels based on ultrasound features like whether a nodule is solid, its shape, and its echogenicity (how bright or dark it appears). In a normal thyroid, these features reliably predict which nodules need biopsy. In a Hashimoto’s thyroid, the system becomes less reliable.
The reason is that Hashimoto’s changes the entire gland’s appearance. The thyroid often looks diffusely enlarged with a dark, heterogeneous texture, and many benign nodules in Hashimoto’s patients appear solid, a feature that would raise concern in the general population. One study found that 63% of benign nodules in Hashimoto’s patients had solid appearances, the same characteristic seen in 100% of malignant ones. This overlap means the usual visual cues don’t separate benign from concerning nodules as cleanly, and some researchers have called for a modified scoring system specifically for Hashimoto’s patients to reduce unnecessary biopsies.
The Cancer Question
This is typically the real concern behind the search. If Hashimoto’s causes nodules, does it also raise your cancer risk? The answer is yes, modestly. A large meta-analysis pooling data from multiple studies found that people with Hashimoto’s have roughly 1.5 to 2.4 times the risk of thyroid cancer compared to people without the condition. The exact figure varies depending on study design, but the association is consistent across research.
That elevated risk sounds alarming in relative terms, but context matters. Thyroid cancer is generally slow-growing and highly treatable, with five-year survival rates above 98% for the most common types. And the vast majority of nodules found in Hashimoto’s patients are benign. The increased risk means closer monitoring is warranted, not that a cancer diagnosis is likely. If a nodule has suspicious features on ultrasound, your doctor will typically recommend a fine needle aspiration biopsy to examine the cells directly.
Will Treating Hypothyroidism Shrink Nodules?
A reasonable assumption would be that taking thyroid hormone replacement to normalize your TSH levels might shrink existing nodules, since elevated TSH contributes to their growth. Unfortunately, the evidence doesn’t support this. Multiple clinical trials have tested whether levothyroxine suppressive therapy reduces nodule size, and the results are consistently disappointing.
In one study, six months of levothyroxine treatment produced no change in nodule size compared to an untreated control group. Other trials spanning 12 to 24 months have shown similarly modest results, with some finding that only 17% to 26% of treated patients see meaningful shrinkage, often not much better than what happens with no treatment at all. The overall conclusion from this body of research is that thyroid hormone replacement treats your hypothyroidism effectively but does not reliably shrink benign nodules once they’ve formed.
This doesn’t mean treatment is pointless. Normalizing your TSH may help prevent new nodules from developing by removing that growth stimulus, even if it can’t reverse existing ones. And managing your hypothyroidism has obvious benefits for energy, metabolism, and overall wellbeing that go well beyond the nodule question.
What Monitoring Looks Like
If you have Hashimoto’s and nodules have been found, the typical approach is periodic ultrasound monitoring. How often depends on the nodule’s size and appearance. Small, clearly benign-looking nodules might be rechecked every 12 to 24 months. Nodules with any suspicious features will usually be biopsied promptly rather than watched.
During a biopsy, a thin needle is inserted into the nodule (often guided by ultrasound) to collect a small sample of cells. The cells are then classified on a standardized scale. The most common finding in Hashimoto’s patients is benign, either showing the expected inflammatory pattern of Hashimoto’s itself or a benign follicular nodule. In rare cases, results may come back indeterminate, which sometimes means a repeat biopsy or closer follow-up rather than immediate action.
The key takeaway is that nodules in Hashimoto’s are common, usually benign, and manageable with routine monitoring. The slightly elevated cancer risk justifies staying on top of your follow-up imaging, but it doesn’t change the fact that the overwhelming majority of these nodules will never cause a problem beyond the anxiety of knowing they’re there.